Supernus Pharmaceuticals (S49) Stock Statistics & Valuation Metrics

Supernus Pharmaceuticals has a market cap or net worth of CHF2.06B. The enterprise value is CHF2.37K.

Supernus Pharmaceuticals has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Supernus Pharmaceuticals’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is -2.58%.

The current PE Ratio of Supernus Pharmaceuticals is ―. Supernus Pharmaceuticals’s PEG ratio is 0.48.

In the last 12 months, Supernus Pharmaceuticals had revenue of 718.95M and earned -38.55M in profits. Earnings per share was -0.68.

In the last 12 months, operating cash flow was 19.91M and capital expenditures -1.12M, giving a free cash flow of 18.79M billion.

Supernus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Supernus Pharmaceuticals upcoming earnings date is Nov 10, 2026, After Close (Confirmed).

Supernus Pharmaceuticals as a current ratio of 1.90, with Debt / Equity ratio of 3.90%

In the past 12 months, Supernus Pharmaceuticals has paid -10.48M in taxes.

Supernus Pharmaceuticals EV to EBITDA ratio is 63.91, with an EV/FCF ratio of 59.10.

Supernus Pharmaceuticals has CHF372.07M in cash and marketable securities with CHF40.17M in debt, giving a net cash position of CHF331.90M billion.

Gross margin is 88.07%, with operating margin of -5.13%, and net profit margin of -5.36%.

The average price target for Supernus Pharmaceuticals is CHF52.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy